HeraMED (ASX:HMD) was incorporated in 2011 in Israel as a technology start-up developing innovative, connected pregnancy monitoring solutions.Its first commercial product, HeraBEAT™ is a medical-grade, clinically validated fetal heart rate monitor mainly for home use.
Today, fetal heart monitoring is a standard part of every pregnancy check-up, but current technologies are expensive, bulky, limited and designed for professional use only. The result is that pregnancy monitoring almost always requires a clinical setting, a nurse or doctor to conduct the measurement and the careful attention of a trained obstetrician-gynaecologist for a subjective, time-consuming, visual interpretation of FHR pattern recognition and assessment.
HeraMED’s aim is to become a world leader in innovative, accessible, technology-driven products which change the way practitioners and expectant mothers approach and monitor the miracle of pregnancy.
Pay by: 2 November 18
List Price: $0.20
Minimum Investment: $2,000
Maximum Investment: $5,000